Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

High PD-1 levels in T cells are associated with an early relapse in lymphoma patients upon autologous stem cell transplantation (2021) Richter S, Jacobs B, Böttcher M, Mackensen A, Mougiakakos D, Völkl S Conference contribution Impact of immunosuppressive treatment on the bioenergetics of T-cells (2021) Karl F, Gamali S, Mackensen A, Mougiakakos D Conference contribution Assessment of educational and social status of survivors of childhood cancer: Data of a single center late effects clinic (2021) Hahn B, Schuster S, Metzler M, Mackensen A, Meidenbauer N Conference contribution Successful treatment of COVID-19 with convalescent plasma in B-cell depleted patients may promote cellular immunity (2021) Kremer A, Kremer A, Willam C, Verhagen J, Achenbach S, Van Der Meiden E, Lang V, et al. Conference contribution Purification and functional characterization of CD34(+) cells from cryopreserved apheresis products of patients with bone marrow infiltrating malignancies (2021) Wendland K, Petkovic S, Aigner M, Strobel J, Mackensen A, Müller F Conference contribution Beta-HCG elevation as first sign of a malignant somatic transformation of a non-seminomatous germ cell tumor (2021) Peuser M, Hartmann A, Schmidt D, Mackensen A, Meidenbauer N Conference contribution Synergy of simultaneous activation of cell death pathways of unfolded protein response and of protein synthesis inhibition converges at IRE1a-immunotoxins generate a therapeutic window (2021) Gsottberger F, Meier C, Ammon AM, Petkovic S, Mellenthin L, Krumbholz M, Metzler M, et al. Conference contribution Identification of human CD4(+) T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential (2021) Verhagen J, van der Meijden E, Lang V, Kremer A, Völkl S, Mackensen A, Aigner M, Kremer A Conference contribution Enasidenib in IDH-2 mutant AML patients with relapse after allogeneic stem cell transplantation (2021) Vasova I, Spörl S, Guggenberger V, Berisha M, Rech D, Behzad A, Brandt A, et al. Conference contribution Improved Pseudomonas exotoxin and Mertansine-based Duotoxins for the treatment of hematologic malignancies (2021) Ammon AM, George R, Mellenthin L, Mackensen A, Mueller F Conference contribution